Smiths Group in talks to sell medical division
UK engineer Smiths Group confirmed on Friday it has been in talks to sell its medical division.
UK engineer Smiths Group confirmed on Friday it has been in talks to sell its medical division.
The group has been looking to sell the unit after an approach by potential buyers including San Diego-based healthcare business CareFusion, according to reports.
Smiths also rejected an approach by private equity group Apax to buy the division for £2.45bn in 2011, saying it did not reflect the value of the business.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Its medical division played a role in the first successful IVF treatment in 1978 with its embryo transfer.
In a statement Smiths said it has received a "preliminary approach" for the medical arm.
"This approach may or may not lead to a transaction," the company said.
"Discussions are at an early stage and a further announcement will be made as appropriate."
The division accounted for about a third of the parent group's headline operating profit last year and 28% of the company's £3bn revenues.
Smiths Medical provides devices for hospitals, emergency services, household use and in specialist medical units.
RD
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Trump wants to colonise Mars – will it happen?
Donald Trump wants to plant the US flag on Mars. Could humans really live there?
By Simon Wilson
-
Klarna postpones US IPO as Trump's tariffs rattle markets
Buy-now-pay-later lender Klarna has postponed its US initial public offering owing to the market turbulence. It is not alone, says Matthew Partridge
By Dr Matthew Partridge